摘要
目的:观察左金丸对食管/贲门癌根治术后反流性食管病和治疗效果,并与甲氧氯普胺作用结果做比较。方法:①选择2004-01/2005-06在南京中医药大学附属医院胸外科住院行食管/贲门癌手术,复诊时确诊为反流性食管病患者9例为对照组,男5例,女4例;年龄(62±7)岁。选择同期在本院治疗的食管/贲门癌术后发生反流性食管病的患者10例为治疗组,男7例,女3例;年龄(59±10)岁。对治疗方案知情同意。②治疗组:口服左金丸(成分:黄连,吴茱萸;湖北施恩堂制药有限公司生产,生产批号:国药准字Z42020288,18g/瓶),3g/次,2次/d,对照组:口服甲氧氯普胺片(国营张家港市制药厂生产,生产批号:国药准字5A08006,5mg/片),10mg/次,2次/d。均用药7d。③用药7d后进行相关症状改善的评分,具体分为泌酸症状评分(包括烧心、泛酸、胸骨后烧灼痛)、胃肠动力症状评分(包括恶心、呕吐、嗳气、上腹部胀满、吞咽困难)、整体症状评分(包括口苦、纳差)。总分为各部分评分之和。评分标准:身体抬高后各症状完全缓解者评为1分,身体抬高后各症状部分缓解者评为2分,身体抬高后各症状无缓解者评为3分。④计量结果差异比较采用t检验。结果:反流性食管病患者19例均进入结果分析。治疗后左金丸组与对照组症状改善的评分总分、泌酸症状评分、胃肠动力症状评分、整体症状评分差异不明显眼穴5.50±1.84雪,穴1.50±0.85雪,穴2.70±0.82雪,穴1.44±0.88雪分鸦(4.67±2.00),(1.22±0.67),(2.78±1.09),(0.75±1.16)分,P>0.05演。结论:左金丸可明显改善食管/贲门癌术后反流性食管病患者症状,作用效果与甲氧氯普胺相当。
AIM： To observe the effect of zuojin wan, on treating gastroesophageal reflux disease （GERD） after resection of esophageal carcinoma or cardiac carcinoma and compare the results with mctoclopramide.
METHODS： ① The experiment was completed in the Department of Cardiothoracic Surgery, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2004 to June 2005. Nine GERD patients were regarded as control group including 5 males and 4 females with the mean age of （62±7） years, and 10 GERD patients were regarded as treatment group including 7 males and 3 females with the mean age of （59±10） years. All patients were told the fact. ② Patients in treatment group were taken orally with zuojin wart （main component： huanglian and wuzhuyu; Hubei Shientang Pharmaceutical Company Limited, batch number： Z4202028g; 18 g/bottle） of the dosage of 3 g each time for twice a day. Patients in control group were taken orally witb metoclopramide （State-operated Zhangjiagang Pharmaceutical Factory, batch number： guoyao zhunzi 5A08006, 5 mg/pill） of the dosage of 10 mg each time for twice a day for 7 days. ③ Seven days after administration, related symptoms were scored as followed： secreting-acid symptom （heartburn, pantothenic acid, buring pain on the back breast bone）, stomach-bowel power （nausea, emesis, belch, full of epigastric region, dysphagia）, and whole symptom （bitter in mouth, involving difference）. The sum total was regarded as the total scores. Scoring criteria： 1 point was regarded as the patients who were completed recovery after body lifting; 2 points were regarded as partial recovery; and 3 points were regarded as none recovers. ④ Measurement data were compared with t test.
RESULTS： Totally 19 GERD patients entered the final analysis. Scores, such as secreting-acid symptom, stomach-bowel power and whole symptom, were not significantly different in treatment group from those in control group ＇after treatment [（5.50±1.84）, （1.50±0.85）, （2.70±0.82）, （1.44±0.88） points; （4.67±2.00）, （1.22±0.67）, （2.78±1.09）, （0.75±1.16） points, P 〉 0.05].
CONCLUSION： Zuojin wan can improve symptoms of GERD patients after resection of esophageal carcinoma or cardiac carcinoma remarkably and the effect is equal to that of metoclopramide.
出处
《中国临床康复》
CSCD
北大核心
2006年第19期30-32,共3页
Chinese Journal of Clinical Rehabilitation
基金
江苏省中医药管理局课题资助项目(H05052)
江苏省教育厅课题资项目(05KJB360159)~~
